NICE and evidence based medicine are not really compatible
Editor-Smith writes of the " [corruption] of evidence based medicine." 1 This corruption or, more correctly, misrepresentation is not exclusively the preserve of the National Institute for Clinical Excellence (NICE), although that organisation typifies the intellectual sloppiness and lack of imagination in the establishment's response to evidence based medicine.
When the founding of the institute was announced, along with the inclusion of evidence based practice in clinical governance, 2 I imagined that the practice of evidence based medicine would now be encouraged among front line clinicians. This has not happened. What has happened is that the centralised, bureaucratic systems that have hamstrung the NHS for decades, with their traditional panoply of expert committees and top down implementation of guidelines, have claimed extra legitimacy by invoking the mantra of evidence based medicine.
Far from encouraging clinicians to practise evidence based medicine, the National Institute for Clinical Excellence imposes a "one size fits all" population view. This is undoubtedly more comfortable for the Department of Health and other parts of the NHS's management than the potential anarchy (from their point of view) that could result from empowering clinicians and patients to make their own decisions. These decisions would be informed both by evidence and by patients' values and expectations, a process that follows from the "[application of] epidemiological principles . . . to the beliefs, judgements and intuitions that comprise the art of medicine," which is the basis of evidence based medicine. 3 Evidence based medicine challenges the legitimacy, power, and influence of expert groups such as the National Institute for Clinical Excellence to make decisions about management. These decisions are instead taken by individual clinicians and (if the clinicians have thoroughly assimilated both the skills and philosophy of evidence based medicine) shared with their patients. 4 The way that the National Institute for Clinical Excellence functions sits uneasily with the practice of evidence based medicine at an individual level. The lack of skills in evidence based medicine among ordinary clinicians 5 means that the institute currently faces no serious challenge to its authority. But it is impossible for a single national committee, or even local implementation initiatives, to tackle more than a fraction of the questions that patients and doctors need to have answered. If subversives such as myself are successful in encouraging others to engage in evidence based medicine, managers and expert groups will sooner or later find that they are consistently behind ordinary clinicians in the understanding and application of evidence in clinical practice.
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We are now posting all direct submissions to our website within 24 Unfortunately, Smith's liberal vision has included equally liberal blindness to real social and political context. For almost 20 years he has used the resources of the BMJ to advocate limited professional responsibility, insisting that we all use the term rationing when what we really mean is that the scope of the NHS should be reduced.
Why is rationing inevitable? The world is awash with money searching for new ways to multiply itself, so why can we not afford to even try to do all that needs to be done? Yes, it's an endless battle for priority against the demands of the rich to get richer, but what else does he expect?
Encouraged by media entirely dependent on advertising, people's appetites as consumers with cash in their pockets are insatiable-and fortunately so, for if those who already have more than they need were ever satisfied, markets would collapse. As citizens, on the other hand, their expectations for unmarketed, unpromoted, unprofitable, but rational care from public services must somehow be reduced. They must be persuaded that science advances too fast for affordable public services. And who defines what's affordable? It is corporate investors, their politicians, their editors, and that part of the public that has not yet understood the massive shift from taxes on income to taxes on spending.
Rather than join patients to fight for resources, those who ration care seek to amputate the rights of citizens to comprehensive care. Some redundant, less necessary, or less popular part of the service must be removed so that there will be sufficient resources for what remains. Advances outside the rationing limits would then go to our wealthiest or most desperate consumers through a legal black market, and private practice would resume its prewar command of professional innovation. Advocates of "fair" rationing systems abdicate responsibility for leadership toward humane priorities. Their policy of appeasement will fail, because those who thrive from chopping bits off the NHS will never be satisfied. The appraisal is fair. It gives a factual account of the evidence for zanamivir and states it clearly. So far so good. What really caused my anger, however, was the "spin" that followed the publication of the guidance. Ministers and civil servants fell over themselves to greet the guidance as if zanamivir was the wonder drug to beat the winter crisis and issued instructions to health authorities that it was to be used regardless of its marginal benefit. They had no concept of the practicalities of dealing with a patient population with flu-like illness and suggested that pharmacists be empowered to give zanamivir by using patient group directions.
Julian Tudor Hart external professor
My anger has also been fuelled by an article in the Observer, in which Sir Michael Rawlins, the chairman of the National Institute for Clinical Excellence, is quoted as saying "How will they feel if one or two of their patients dies of flu?" in response to a question about general practitioners who do not wish to prescribe zanamivir. 3 If it is a true quote it contradicts the institute's guidance (no impact on mortality has been proved), and it gives a perception that Sir Michael agrees with the spin doctors.
To my mind, the problem is not so much with the National Institute for Clinical Excellence as with the manipulation of its work by politicians. We should take a lesson from Scotland. The SIGN network (Scottish intercollegiate guidelines network) is producing evidence based guidance at arm's length from the government, and its work is almost universally respected. The zanamivir episode could be a turning point for the institute, but not for the better. Latest decision on zanamivir will not end postcode prescribing
Editor-I agree with the opinions expressed in Smith's editorial on the National Institute for Clinical Excellence (NICE). 1 As the prescribing lead general practitioner for our primary care group I am faced with an estimated 7% overspend on our current budget. The institute's guidance on zanamivir (Relenza) is going to compound our problems. 2 This might be bearable if the decision had been made with proper regard to evidence based medicine. The scientific review is sloppy and acknowledges that the institute has no idea of the workload implications for primary care stemming from its recommendations.
The evidence for reconsidering zanamivir is derived from the manufacturer's trial, which is hardly unbiased; it might have been more compelling if there was a comparative trial of zanamivir and amantadine. The institute admits that it was not asked to look at alternative treatments. In at risk patients the duration of symptoms is reduced by 1.2 days, from six to five days, and complications requiring antibiotics are reduced by 6%. Neither of these outcomes is a reliable measure as symptoms are subjective and the decision to prescribe antibiotics in viral infections is not usually scientific or rational. For the important outcomes such as mortality and admission to hospital there are no data. None of the outcomes justifies the decision to recommend prescription of this drug.
The institute estimates the quality adjusted life year cost of its recommendations as lying between £9 300 and £31 500 (over a threefold variation); the workload is estimated at between an extra 3 and 17 patients per general practitioner per week (over a fivefold variation); and the cost is estimated at between £2.3m and £11.7m in drug costs alone.
The decision to make the recommendation is extraordinary given the minimal benefits and huge uncertainty about the financial and workload implications. The National Institute for Clinical Excellence has power but no responsibility, as the cost implications are borne by general practitioners and primary care groups. This will lead-as has already started to happen-to local decisions being made about the affordability of its decisions. This is postcode prescribing, which setting up the institute was meant to avoid. The only solution would be for the government to fund the extra costs of its recommendations. This would be welcome but, given that the institute has not the remotest clue about costs, rather difficult to implement.
I look forward to the replacement of NICE by CHOR (the Committee of Honest and Open Rationing) as Smith suggests.
Mike Powell general practitioner
Boathouse Surgery, Pangbourne, Berkshire RG8 7DP powellmp@compuserve.com
Editor's choice of acronym for new NICE is Punjabi for thief
Editor-Although the BMJ is always informative and frequently entertaining, I had never thought that it would provide occasion for hilarity. But the last sentence of Smith's editorial on the National Institute for Clinical Excellence (NICE) had me-and, I'm sure, many other readers of North Indian or Pakistani origin-laughing out loud. 
Doctors treating patients with multiple sclerosis will lose confidence in NICE
Editor-It is time the profession signalled its lack of confidence in the National Institute for Clinical Excellence (NICE). I hoped I was wrong when in 1999 I wrote, "I can only conclude that [the institute's] true purpose is to deprive patients of treatment by delay," 1 but events, at least for patients with multiple sclerosis, have proved me correct.
The fourth of the institute's stated aims was to "Avoid significant delays." Let us look at the facts. x In 1993 interferon beta was found to be an efficacious treatment for relapsingremitting multiple sclerosis. 2 x In 1995 the NHS Executive asked purchasers and providers to develop and implement a prescribing approach to interferon beta. 3 x In 1999 the institute announced that it would start evaluating interferon beta in August 1999 and that guidance to the NHS would be issued in August 2000 (NICE press release, 1999: "NICE technology appraisals: programme of results announced" (1999/ 012)).
x On 22 December 2000 the chief executive of the institute, Andrew Dillon, announced that a decision on the use of interferon beta would not be considered again until the appraisal committee meets in July 2001 (NICE press release: "NICE to commission further research on MS drugs" (2000/052)).
x In 2001, patients in the United Kingdom with clear indications for interferon beta are being deprived of treatment more than seven years after it was shown to be safe and effective.
Peter Cardy, chief executive of the MS Society, has branded the institute as inept. I think he is being too kind. There is nothing inept about this delay. It is a deliberate attempt to delay a potentially embarrassing decision until after the general election.
Most of us in the medical profession would welcome a rational and efficient rationing system. We would expect it to be "ethical, explicit, transparent, fair, flexible, consistent, and capable of timely response to development." 1 The National Institute for Clinical Excellence is none of these. Most of us would consider it unethical to enter a conspiracy to deprive patients of proved treatment without good reason. Those members of our profession involved in the institute should examine their consciences.
It is time for the medical profession to signal its lack of confidence in the National Institute for Clinical Excellence. To do otherwise would be to betray the trust that our patients place in us as advocates on their behalf.
Simon J Ellis consultant neurologist
North Staffordshire Royal Infirmary, Stoke on Trent ST4 7LN Simon@northesk.demon.co.uk
NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal
Editor-The National Institute for Clinical Excellence (NICE) has offered guidance on the use of rosiglitazone for type 2 diabetes mellitus.
1 In paragraph 1.2 this states that "patients with inadequate blood glucose control on oral monotherapy (metformin or sulphonylurea) should first be offered metformin and sulphonylurea combination therapy, unless there are contraindications or tolerability problems."
The United Kingdom prospective diabetes study investigated aggregate end points for patients treated with metformin and a sulphonylurea. 2 In those taking combination treatment compared with those taking sulphonylurea alone, diabetes related deaths were increased with a relative risk of 1.96 (P = 0.039) and all cause mortality was increased with a relative risk of 1.60 (P = 0.041). Caution was advised in interpreting these data as there were relatively few events, but the differences were significant. Nevertheless, the National Institute for Clinical Excellence has suggested a drug combination which may delay insulin treatment and is used by many clinicians but is not supported by the evidence.
The evidence for the use of rosiglitazone is based on its addition to metformin or a sulphonylurea rather than its substitution for metformin or a sulphonylurea. 1 3 Many patients with type 2 diabetes mellitus who have come to combination sulphonylurea and metformin and have suboptimal glycaemic control will be developing cell failure and could require insulin treatment. The prescription of rosiglitazone at a late stage of type 2 diabetes mellitus means that it will be used for a relatively short period, if at all, before insulin is required. Does the National Institute for Clinical Excellence's guidance suggesting the use of rosiglitazone later than is ideal, unsupported by evidence based medicine, amount to rationing? 
Foundation is helping carers to reduce risk of sudden infant death syndrome
Editor-Gottlieb reports that more cases of the sudden infant death syndrome (cot deaths) occur in day care than at home. Since 1996 the Foundation for the Study of Infant Deaths has recognised that carers have been a neglected group for receiving advice on reducing the risk of the syndrome, information about cot deaths, and bereavement support. The foundation has held seven one day conferences-"Holding the baby"-especially tailored for nannies, nursery nurses, childminders, and foster carers. At these conferences we offer advice on how to reduce the risk of the sudden infant death syndrome and how to provide support when a baby dies suddenly and unexpectedly. As a result of these conferences and the information shared, delegates have left to draw up their own guidelines, some of which include holding a drill. The need for support for foster carers has been highlighted.
The foundation has also recognised the need for babysitters to receive the "reduce the risk" message and has produced some guidelines for what to do in an emergency. "Care with confidence" is the latest leaflet to be produced, following on from the "Are you babysitting tonight?" leaflet.
Gottlieb reports a study in the United States; that country lags behind the United Kingdom in promoting total population intervention. Not all cases of the sudden infant death syndrome that occur in someone else's care are due to neglect or failure to follow the guidelines to reduce the risk: babies at higher risk, such as babies of drug misusers, are more likely to be in day care or to be fostered.
The Foundation for the Study of Infant Deaths is continuing to promote the reduce the risk message to all carers with further conferences and talks to nurseries and schools. Its 24 hour helpline (020 7233 2090) is also available to all carers.
Ann Deri-Bowen national coordinator
Foundation for the Study of Infant Deaths, London SW1P 1RT support@sids.org.uk
Needle length and incidence of local reactions to immunisation
How quickly can research change practice?
Editor-The paper by Diggle and Deeks was fast tracked in the hope of avoiding the five year delay that often occurs between the emergence of new evidence and a change in practice. 1 I think that in this case there has already been major delay. A Medline search quickly produces several papers on this subject. Ipp et al noted that more redness and swelling occurred in children injected in the thigh with a 16 mm needle than with a 25 mm needle. 2 The nature of the evidence also needs to be considered. This study used a standardised injection technique, but other techniques are used in practice, and Groswasser et al reported that injection technique is the most important variable in ensuring efficient delivery of intramuscular vaccine. 3 Consequently, the injection technique chosen determines the appropriate needle size.
The question of which needle length is preferable has been around for a long time, and the answer is relatively easy to obtain. We might still have to wait several years, however, for any change in practice. 
Further research is needed before practice is changed
Editor-The study by Diggle and Deeks on needle length and local reactions could lead to an interesting change in practice, although I do have several criticisms of the study and think that further research is needed. 1 Firstly, I am surprised by the design of the study, as no attempt was made to use equal bore sizes and hence remove this conflicting variable. As a result the conclusions are weakened and the reader could equally deduce that the effect was due to the different bore sizes and not, as the authors suggest, the needle length.
Secondly, no independent observer was used to objectively assess redness, swelling, and tenderness. Instead, parents were used; they were not blinded in any way, and their interpretations of these effects could have varied.
Finally, the study also fails to show any significant difference in tenderness, which from the babies' point of view is the most important factor. It is possible that the same local reaction occurs with both needle lengths, causing equal tenderness, and it is merely that the injection with the shorter needle is closer to the skin surface. It would have been of interest to know if the use of analgesics differed between groups or if any local reaction was severe enough for it to require medical attention. Otherwise the findings are only important for the skin and do not warrant a change in practice. Needle gauge is more important than needle length
Editor-Diggle and Deeks claim that 25 gauge needles cause more severe local reactions because they are shorter than 23 gauge needles. 1 It is likely that 25 gauge needles cause more trauma because they have a narrower bore and not because they are shorter. The 25 gauge needle produces a jet under higher pressure, which causes much more local damage to the tissue. The 23 gauge needle, whatever its length, produces less trauma and therefore less severe local reactions.
Irrespective of underlying cause, the conclusion-that we should be using 23 gauge needles-is the same. I welcome the authors' recommendation that manufacturers should review their policy of supplying 25 gauge needles in vaccine packs. 
Mando Watson locum consultant paediatrician

Authors' reply
Editor-The correspondents raise concerns about blinding, the non-significance of the difference in tenderness, and potential confounding of needle bore and needle length in our study. Critical review of the studies cited by Platt confirms that the question of needle size and local reactogenicity has not previously been studied in this age group. It seems unlikely that the observed differences are exaggerated through parental recording of reactions. Parents were not told which needle their child received. Although this blinding mechanism is not secure, anecdotal evidence indicates that any resulting bias would be in favour of the smaller needle-parents clearly perceive longer needles to be more painful. The use of an independent observer to monitor reactions in each child's home was not feasible.
The non-significant difference in tenderness with the different needles must be interpreted with caution. It would be wrong to conclude "evidence of no difference"-the correct interpretation is "no conclusive evidence of a difference." In fact tenderness was reduced by the same magnitude as redness, but as tenderness occurred less frequently the results were not statistically significant. We can gauge how likely it is that longer needles are compatible with clinically significant increases or decreases in tenderness by using bayesian analyses (with "uninformative prior" distributions). When the trial was being designed, relative differences of 25% in tenderness were considered clinically significant. At six hours the probability of a clinically significant increase in tenderness with the longer needle was 2%, whereas the chance of a clinically significant decrease was 73%. Although the analysis did not reach statistical significance, the data give no support to the hypothesis that tenderness is increased by deeper vaccinations given with the longer needle.
The needles selected for comparison were those that we observed being used in general practice in a survey of 102 practice nurses. Although it would have been interesting to have compared both length and bore, nobody in our survey was using the 25 gauge 25 mm needle or the 23 gauge 16 mm needle. Other studies comparing same bore needles of different lengths or same bore needles injected at different depths have noted similar findings, 1 2 so the observed difference is more likely to be related to length than to bore.
Although there are unanswered questions about other needles and other adverse effects, we found that the 23 gauge 25 mm needle is better than the 25 gauge 16 mm needle currently packaged with the vaccine. We recommend routine use of the longer needle in infant immunisation until further research indicates otherwise. 
Linda Diggle senior research nurse
Is there a real benefit for the child?
Editor-It is certainly comforting to see fewer local reactions with the use of longer immunisation needles. 1 One has to ask, however, whether this is a real advantage for the vaccinated child and not just for the observing parents and caregivers. The same degree of local inflammation-the basis for erythema and inflammation at the injection site-may occur with deeper injections but may simply be less visible and palpable compared with the use of conventional, shorter immunisation needles.
To see if there is a real benefit for the child, I would have liked to see reported the rates of other common adverse events following immunisation in infancy, such as fever, disturbed night sleep, poor feeding, and prolonged crying. A statistically significant decrease in the occurrence of these less specific events, which may interfere with family peace for a few days, would be the ultimate proof of benefit. The observed tendency of less tenderness (how was this assessed in young infants?) seems to point in the right direction. However, a larger study may be needed to show statistically significant differences. 
Ulrich Heininger consultant in paediatric infectious diseases and vaccinology
Comparison of St John's wort and imipramine
Remission is important outcome
Editor-The authors of either of the two large trials of St John's wort for treating depression published in the BMJ have reported the proportion of patients entering full remission of symptoms after acute treatment. 1 2 This is unfortunate as remission of symptoms rather than response to treatment should be the key outcome objective. Partial remission is a common adverse outcome of depression after short term treatment and carries with it a high risk of relapse and continuing disability. 3 There is now emerging evidence that although all antidepressants seem to be similarly efficacious in producing a short term response, there are differences in remission rates, particularly in severely ill patients. 4 This shows the importance of reporting categorical as well as continuous outcomes in clinical trials of treatment with antidepressants. 
Peter L Cornwall senior lecturer in community psychiatry
Study design casts doubt on value of St John's wort in treating depression
Editor-Although it is impressive to see a study in which hypericum is equivalent to an antidepressant, suggesting efficacy, the design of this study by Woelk et al makes it difficult for us to know the value of St John's wort for the treatment of depression. Firstly, imipramine is an outdated antidepressant. The current batch of selective serotonin reuptake inhibitors and atypical antidepressants have far fewer side effects and can be tailored to the specific needs and responses of the patient. Will hypericum be coupled with activating herbs (such as Gingko biloba or Siberian ginseng) or sedating ones (such as kava or valerian root) to achieve the same effect? This study strikes me as an example of statistical interest (yes, hypericum may be at least as effective as imipramine), but it has minimal practical clinical relevance.
Secondly, the study ran for only six weeks. Most studies exploring the efficacy of an antidepressant run for a substantially longer period. Various factors can come into play after this initial period. Do subjects discontinue use due to long term side effects they are willing to put up with in the short term? Does an initial placebo effect run its course, and then the two drugs have differential efficacy? What is the impact of either drug on recurrence? A longer trial reveals a tremendous amount, whereas such a brief trial only leaves us wondering as to its veracity.
Thirdly, without a comparison group that received no active drug, we have no way of knowing if either treatment has much benefit beyond natural improvement or placebo. The is because of the natural course of the disease (especially if a significant proportion of the subjects had an adjustment disorder with depressive mood, which tends to resolve on its own). In addition, the placebo effect is even higher when the placebo has some antihistamine effect (similar to the influence of the antidepressant on histamine receptors). In earlier studies imipramine may have been similar to inert placebo, thus making current comparisons and analysis of effect sizes difficult, if not impossible.
Thus, any replication of this study may want to consider hypericum versus a more modern antidepressant, a course of treatment that runs for six months, not six weeks, and a third arm to the study that uses a placebo with some antihistamine to mimic the immediate physiological effects of the active medicines in the other arms of the study. 
Finding must be treated with caution
Editor-Although the trial reported by Woelk et al was designed to avoid the limitations of other hypericum trials, it still has many limitations. 1 The dose of imipramine was increased from 25 mg twice daily to 75 mg twice daily in one week, which does not represent current clinical practice. This played a part in the higher rates of withdrawal symptoms and side effects in this trial. In a meta-analysis by Linde et al the dropout rates due to side effects for hypericum and different types of tricyclic antidepressants were 2.2 and 6.8, respectively. 2 The dosage of imipramine should be individually determined according to the requirements of each patient and increased gradually according to the clinical response. A lag in therapeutic response usually occurs at the onset of treatment, lasting from several days to several weeks; increasing the dosage does not normally shorten this latent period and may increase incidence of side effects. 3 It would be more appropriate if the sample size was calculated by using a two tailed test, which will increase the sample size by 25 patients in each group. Woelk et al showed that patients who have anxiety associated with depression may derive more benefit from treatment with hypericum than with imipramine, which is an interesting finding, especially in a general practice setting where it might be difficult to draw a distinct line between mild to moderate depression and anxiety disorders. This finding must be interpreted with caution, since imipramine is not indicated for the treatment of anxiety disorders. 
Sensitivity of assay is questionable
Editor-Woelk et al have undertaken to confront the criticism of design and methods of some studies evaluating the efficacy of hypericum by attempting to conduct a trial that meets current methodological standards. 1 Their report does, however, also seem to have methodological shortcomings.
Firstly, owing to the absence of a placebo control group, the magnitude and relevance of the 'treatment effect' cannot be assessed and therefore the trial's assay sensitivity cannot be demonstrated. 2 Woelk et al report 43% of patients in the hypericum group and 40% in the imipramine group whose scores on the Hamilton depression scale decreased by at least 50% against baseline, Linde et al found rates of "50% responders" of up to 54% in the placebo groups of the trials included in their review. 3 Therefore the treatment effect in this trial could alternatively be explained by a placebo effect, since there is no proof that the trial was appropriate to discriminate between pharmacologically active and inactive treatments. Although the absence of a placebo control group is an issue in most active control trials, a proof of assay sensitivity seems to be particularly essential in depression, owing to the very large extent and variability of the placebo effect.
Secondly, the non-inferiority margin used in the trial is debatable. Woelk et al claim that a difference in improvement <3.5 points between hypericum and imipramine on the 17 item Hamilton depression scale is clinically irrelevant. But taking into account that an effect size of 3 points is accepted as clinically relevant to distinguish between an active drug and placebo, 4 this non-inferiority margin seems much too large. It was larger than the significant differences between hypericum and placebo in several of the trials reviewed by Linde et al, 3 and it would permit to accept non-inferiority even if hypericum were no more efficacious than placebo. 2 Thirdly, the actual standard deviation of the primary variable turned out to be only about half of the value assumed during sample size calculation. This strongly indicates that there are essential differences between this study and earlier trials, causing doubts on its external validity.
Fourthly, although the trial was designed to show the non-inferiority of hypericum extract in comparison to imipramine by a one sided non-inferiority test, Woelk et al report the result of a (non-significant) two sided superiority test for the primary variable. 
Andreas Völp independent biostatistician
Author's reply
Editor-The proportion of patients having full remission of symptoms after acute treatment is one way of defining the key outcome objective. Yet, clinically, partial remission is defined as at least a 50% reduction on the Hamilton depression rating scale, which corresponds to very much or much improved on the clinical global impression scale. Such an improvement is clinically relevant, and most of the conducted trials of antidepressants have used it. Six weeks is a reasonable time for a short term trial looking at the efficacy and tolerability of antidepressants.
2 It is not ethical to treat patients with a depressive disorder for longer than this in a placebo controlled study.
The Ze 117 extract of St John's wort has also been tested against fluoxetine, a more modern antidepressant. This trial showed that the efficacy of Ze 117 was equivalent to that of fluoxetine 20 mg daily. 3 An open multicentre long term study in 440 patients concluded that Ze 117 250 mg twice daily for up to 12 months is a safe and effective treatment in patients with mild to moderate depression. 4 The dose of imipramine was indeed increased to its therapeutic concentration comparatively quickly. Yet the number of participants who dropped out because of adverse events was similar to that in other trials. 5 Of course any trial can always be improved, especially by having an additional arm that includes placebo, but the large response to our study, both negative and positive, shows fair criticism of our study of a herbal product.
Addison's disease: after 40 years much remains the same
Editor-Hilditch was diagnosed as having Addison's disease 40 years ago, when blood tests were more expensive and less frequently used for general screening than they are now. 1 Her experience that the disease was not diagnosed until she was near death is, however, still common to many patients today and prompts the remark that "Getting diagnosed is the hardest part of this disease.'' Early detection of Addison's disease is not easy: non-specific symptoms and fatigue may be overlaid by signs of depression (as is also the case with hypothyroidism). Some patients never develop the full classical triad of hyperpigmentation, hypotension, and hyponatraemia. The nature of the disease also means that patients who have struggled with subclinical symptoms for years as their adrenal function deteriorates suddenly become vulnerable to a crisis when they meet flu or another illness which they no longer have the adrenal reserves to combat. Some patients report having been admitted to hospital with a crisis more than once before their disease is diagnosed.
In some cases, the reluctance of medical practitioners to consider an uncommon cause of disease remains a factor in late diagnosis. It is only four years since a Lesson of the Week in the BMJ documented the deaths of two young patients whose Addison's disease was not diagnosed until necropsy. 2 The first of these deaths took 
Editorial on management of anal warts is misleading
Editor-In their editorial on the management of anal warts, Maw and von Krogh say that podophyllin, 5-fluorouracil, and interferons are no longer recommended for use in primary care because of their low efficacy and toxicity. 1 This statement is referenced to the current British national guidelines on the management of sexually transmitted infections and closely related conditions and to an article by von Krogh et al. 2 3 Firstly, the British national guidelines do not state that podophyllin is unsuitable for home use, but that a 0.5-2.0% podophyllin solution applied by the patient at home has shown comparable results to the application of a 15-25% solution applied in the clinic setting. Edwards et al showed that weekly podophyllin and podophyllotoxin had the same efficacy. 4 Application twice weekly could well prove more efficacious than podophyllotoxin.
Secondly, the guidelines make no reference to the use of either 5-fluorouracil or interferons in primary care.
Thirdly, the editorial statement was quoted directly from the original article by von Krogh et al and is not referenced there. Thus the information from the BMJ editorial is misleading and has prompted three enquiries from local general practitioners.
There is currently no published robust head to head study comparing all the treatment modalities currently used in the management of anogenital warts. Provisional results of a regional audit showed that of nine clinics for genitourinary medicine surveyed in the Oxfordshire Deanery (41 doctors responding to the audit questionnaire) there were at least five commonly used therapeutic combinations and less than half the practitioners used only one modality at any one given time (unpublished data).
Maw and von Krogh do not address the issue of combination treatment at all, although unlicensed podophyllin has been in regular use for 30-40 years. In a cash strapped NHS with an epidemic of genital wart virus infection, we need convincing studies proving lack of efficacy before recommending products such as imiquimod as first line treatment. (four weeks' treatment £57 compared with £3 for podophyllin).
The title of the editorial by Maw and von Krogh did not reflect that the discussion included both anal and genital warts, which has further contributed to the confusion. Colleagues thought that Maw and von Krogh meant anal warts and therefore have not reacted to the editorial because the use of podophyllin for anal warts is thought by some to be inappropriate in primary care. 
Access to undergraduate medical education is being broadened
Editor-Sheffield is not alone in making plans for the development of schemes to widen access to higher education as discussed by Angel and Johnson. 1 The City of Glasgow incorporates as much as 60% of the areas of greatest deprivation in the United Kingdom. The number of school leavers from the west of Scotland who enter higher education is about half the national average (28.3% compared with 48% for higher education and 16% compared with 29.5% for university admission) and in extreme cases participation rates in higher education are as low as 4%. 2 3 In addition, although the proportion of young people in Scotland participating in higher education rose to 48%, that from underrepresented socioeconomic groups was only 15%.
The GOALS (Greater Opportunity of Access and Learning with Schools) project aims to widen access to higher education in the west of Scotland. It provides a spectrum of opportunity for school pupils, from age 10 to 18, to learn about and become familiar with higher education. It is targeted at schools with low rates of progression. Through a range of mechanisms, spanning all school years from primary 6, higher education institutions in the west of Scotland make and maintain contact with school pupils to encourage them towards higher education. The project includes a range of activities to motivate school pupils including school visits by student mentors, supported study, visits to university campuses, and advice for pupils, parents, and teachers. The faculty of medicine is also taking part in the "Saturday university" sessions aimed at giving the schoolchildren a taster of what medicine might be like as a career, sessions facilitated by staff and undergraduate medical students.
In 1999, five (0.43%) of the applications received by the Faculty of Medicine in Glasgow were from those living in areas covered by the GOALS scheme. Two were successful in obtaining places; the other three failed to reach the required academic standard. There is no positive discrimination in Glasgow, although when the applicants attend for interview the interviewers are aware that the applicant is from a school in a deprived area. The university is uneasy with the idea of positive discrimination because it could lead to the accusation of unfairness. Instead, we are keen to develop strategies to identify suitable doctors of the future at an early stage when they can undergo appropriate training that will enable them to reach the required standard by the time of application. This system is being used successfully in the United States. since there has been a move away from positive discrimination as a result of successful legal challenge. 4 We support Sheffield's aim in allowing flexibility but feel objective criteria are essential so that there is no opportunity for bias in a highly competitive admissions procedure that should be transparent. 
